Detalhe da pesquisa
1.
Comparative Bioavailability of a Novel Solution and a Tablet Formulation of Levothyroxine.
Clin Pharmacol Drug Dev
; 12(5): 502-508, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36876643
2.
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Diabetes Care
; 30(2): 217-23, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17259484
3.
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
Diabetes Care
; 41(2): 333-340, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242349
4.
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.
Diabetes Care
; 41(3): 613-619, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29301824
5.
PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
Diabetes Care
; 28(9): 2093-9, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16123472
6.
Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Curr Med Res Opin
; 20(6): 883-9, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15200747
7.
Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Postgrad Med
; 126(3): 111-25, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24918797
8.
Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
Postgrad Med
; 126(3): 172-89, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24918802
9.
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
J Diabetes Complications
; 28(3): 393-8, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24631129
10.
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Clin Ther
; 35(5): 634-645.e1, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23578605
11.
Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
Diabetes Care
; 36(9): 2559-65, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23645886
12.
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Diabetes Care
; 26(12): 3361-2; author reply 3362-3, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14633839
13.
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Vasc Health Risk Manag
; 4(6): 1167-78, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19337530
14.
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Diabetes Care
; 31(1): 30-5, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17947341